23 / 28
Notes:
Volume 6, Issue 4 (Suppl)
Clin Pharmacol Biopharm, an open access journal
ISSN: 2167-065X
Page 47
Euro Biopharma & Ethnopharmacology 2017
November 09-11, 2017
&
6
th
International Conference and Exhibition on
November 09-11, 2017 Vienna, Austria
4
th
EUROPEAN BIOPHARMA CONGRESS
PHARMACOLOGY AND ETHNOPHARMACOLOGY
Joint Event
New compounds from
Withania Somnifera
with neuroprotective activities. Isolation, structure elucidation
bioassays and scale-up production
Géraldine Le Goff
1
, Guillaume Arcile
1
, Chérif Rabhi
2
, Léon Cariel
2
and
Jamal Ouazzani
1
1
Institut de Chimie des Substances Naturelles - CNRS, France
2
Ethnodyne, France
T
he prevalence of neurodegenerative diseases are increasing worldwide due to extensions in lifespan with more than 2.1 billion
people aged 60 and more in 2030. The most representative diseases are Alzheimer’s disease (AD), Parkinson’s disease (PD),
Amyotrophic lateral sclerosis (ALS), and Huntington’s disease (HD). Available treatments are limited in number and efficacy and
extensive efforts are dedicated to alternative herbal therapy. Among various promising plants,
Withania somnifera
roots and leaves
extracts demonstrated large spectrum activities on neural dysfunction (common name Ashwagandha). Based on our previous
encouraging results, our ongoing efforts are dedicated to identify new compounds from Ashwagandha and demonstrate their
mechanism of action and their relevance in neuroprotection. Besides the known major constituents, withanolides, withanone and
withaferin, now steroidal components were identified and their biological activity investigated.
Geraldine.LEGOFF@cnrs.frGéraldine Le Goff et al., Clin Pharmacol Biopharm 2017, 6:4(Suppl)
DOI: 10.4172/2167-065X-C1-025